CD8-mIL2 outperformed CTRL-not-α-mIL2 in both the MC38 and the 3-methylcholanthrene (MCA) induced d42m1-T3 sarcoma (T3) models (Fig. 4G–K), demonstrating both superior antitumor activity and reduced body weight loss. This evidence concerns the gene CD8A and sarcoma.